Biosurgical Agents | Market Insights | Asia Pacific (Supplemental) | 2022
The COVID-19 pandemic has negatively impacted the Asia Pacific biosurgical agent market due to the deferral or cancelation of elective and semi-elective procedures; however, following a period of recovery, the market will subsequently grow at a modest rate, driven by growing surgical procedure volumes due to the expanding aging population and the rising prevalence of diseases associated with aging, obesity, diabetes, and cardiovascular disease. However, growing concerns over product cost and competition from local competitors will limit ASP growth in this market, hindering revenue expansion to some extent.
This Medtech 360 Report provides high-level market metrics for biosurgical agents in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the Asia Pacific region, across an 11-year period.
